Cheng-ho Jimmy Lin
Founder and President of the Rare Genomics Institu
Medicine
Angiogenesis Foundation
Sweden
Biography
Cheng-Ho Jimmy Lin, MD, PhD, MHS, a pioneer in cancer genomics, served as the Director of Clinical Genomics at the Genetics Branch of the National Institute of Health/National Cancer Institute (NIH/NCI). At Johns Hopkins University and Washington University in St. Louis, Dr. Lin was part of one of the first clinical genomics laboratories to lead the computational analyses of the first ever genome sequencing studies (including breast, colorectal, glioblastoma, medulloblastoma, melanoma, and pancreatic). He has published in top academic journals, including Science, Nature, and Cell, and is a consultant to national and international media outlets. Dr. Lin holds an MHS in bioinformatics, a PhD in cellular and molecular medicine, an MD from Johns Hopkins University, and majored in cognitive science, molecular biophysics, and biochemistry at Yale University. He is a 2012 TED Fellow and a 2016 Senior TED Fellow. Currently, he is the Chief Scientific Officer of Oncology at Natera and the Founder and President of the Rare Genomics Institute.
Research Interest
Cheng-Ho Jimmy Lin, MD, PhD, MHS, a pioneer in cancer genomics, served as the Director of Clinical Genomics at the Genetics Branch of the National Institute of Health/National Cancer Institute (NIH/NCI). At Johns Hopkins University and Washington University in St. Louis, Dr. Lin was part of one of the first clinical genomics laboratories to lead the computational analyses of the first ever genome sequencing studies (including breast, colorectal, glioblastoma, medulloblastoma, melanoma, and pancreatic). He has published in top academic journals, including Science, Nature, and Cell, and is a consultant to national and international media outlets. Dr. Lin holds an MHS in bioinformatics, a PhD in cellular and molecular medicine, an MD from Johns Hopkins University, and majored in cognitive science, molecular biophysics, and biochemistry at Yale University. He is a 2012 TED Fellow and a 2016 Senior TED Fellow. Currently, he is the Chief Scientific Officer of Oncology at Natera and the Founder and President of the Rare Genomics Institute.
